Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Masimo Needs Rainbow To Lead To A Pot Of Gold

Over and over again, investors who follow the med-tech space will see examples of companies generating solid revenue and profit growth in markets that are seen as slow-growth. In the case of Masimo (NASDAQ:MASI), the company has used strong technology to add some spice to the pulse oximetry market. More recently, though, the company has struggled to generate the hoped-for growth from hemoglobin monitoring. Better execution here is the real key to the story - if Masimo can translate the potential of noninvasive hemoglobin monitoring into real sales, there could be upside to these shares.

Familiar Themes Closed Out 2012

Masimo's recent fourth quarter report was in some respects a microcosm of the company's story in recent quarters...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details